IBSA USA
Mark Oliver is an experienced pharmaceutical sales professional with a robust background spanning over two decades. Currently serving as a Specialty Sales Representative at IBSA USA since July 2023, Mark has previously held the same position at Idorsia Pharmaceuticals Ltd from July 2022 to March 2023. Prior to that, Mark was with AstraZeneca for nearly 18 years, where responsibilities included Cardiovascular Sales Specialist and Diabetes Sales Specialist, among other roles. Mark began a career in pharmaceutical sales at PDI, Inc., focusing on primary care and specialty sales in psychiatry. Mark holds a Master of Business Administration (MBA) from Le Moyne College, specializing in Business, Management, Marketing, and Related Support Services.
This person is not in any teams
IBSA USA
IBSA USA is the subsidiary of IBSA Group, the largest privately owned pharmaceutical company in Switzerland. IBSA is committed to improving patient quality of life through research, innovation, and the development of effective drugs and cutting-edge technologies. IBSA USA markets two unique levothyroxine formulations in the U.S. for the treatment of hypothyroidism: Tirosint® (levothyroxine sodium) capsules and Tirosint®-SOL (levothyroxine sodium) oral solution. IBSA also markets Licart™ (diclofenac epolamine) topical system 1.3%, the only once-a-day topical nonsteroidal anti-inflammatory (NSAID) available in the U.S. to treat acute pain due to minor strains, sprains, and contusions. IBSA is focused on the health and well-being of patients and driven by the desire to bring therapeutic alternatives to as many people as possible. IBSA Group bases its philosophy on four sustainable pillars: Person, Innovation, Quality, and Responsibility. For more information about Tirosint, Tirosint-SOL, or Licart, including Full Prescribing Information, go to each brand’s respective website.